Appendix II — J — Decisions Cited — J
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
Jackson, Ex parte, 217 USPQ 804 (Bd. Pat. App. & Inter. 1982) 2164.06 , 2164.06(a) , 2404.02
Jaffe, Ex parte, 147 USPQ 45 (Bd. of App. 1964) 1504
J. A. La Porte, Inc. v. Norfolk Dredging Co., 787 F.2d 1577, 229 USPQ 435 (Fed. Cir. 1986) 2133.03(b)
Janakirama-Rao, In re, 317 F.2d 951, 137 USPQ 893 (CCPA 1963) 2111.03 , 2163
Jansen v. Rexall Sundown, Inc., 342 F.3d 1329, 68 USPQ2d 1154 (Fed. Cir. 2003) 2111.02
Janssen Biotech, Inc., In re, 880 F.3d 1315, 125 USPQ2d 1525 (Fed. Cir. 2018) 804.01 , 1481.03 , 2258
Jazz Pharm., Inc. v. Amneal Pharm., LLC, 895 F.3d 1347, 127 USPQ2d 1485 (Fed. Cir. 2018) 2128 , 2152.02(e)
Japikse, In re, 181 F.2d 1019, 86 USPQ 70 (CCPA 1950) 2144.04
J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred Int’l, Inc., 534 U.S. 124, 60 USPQ2d 1865 (2001) 2105 , 2106.04(b)
Jennings, In re, 182 F.2d 207, 86 USPQ 68 (CCPA 1950) 1504.03
Jentoft, In re, 392 F.2d 633, 157 USPQ 363 (CCPA 1968) 804.02 , 1490
Jessel v. Newland, 195 USPQ 678 (Comm’r Pat. 1977) 1605
Jockmus v. Leviton, 28 F.2d 812 (2d Cir. 1928) 2121.04 , 2125
John O. Butler Co. v. Block Drug Co. Inc., 620 F. Supp. 771, 226 USPQ 855 (D. Ill. 1985) 1504
Johns-Manville Corp. v. Guardian Industries Corp., 586 F. Supp 1034, 221 USPQ 319 (E.D. Mich. 1983) 2165.01
Johnson, In re, 282 F.2d 370, 127 USPQ 216 (CCPA 1960) 2164.01(c)
Johnson, In re, 558 F.2d 1008, 194 USPQ 187 (CCPA 1977) 2164.08 , 2173.05(i)
Johnson, In re, 589 F.2d 1070, 200 USPQ 199 (CCPA 1978) 2161.01 , 2184
Johnson, In re, 747 F.2d 1456, 223 USPQ 1260 (Fed. Cir. 1984) 716.02(e)
Johnson & Johnston Assoc. Inc. v. R.E. Serv. Co., 285 F.3d 1046, 62 USPQ2d 1225 (Fed. Cir. 2002) 2173.02
Johnson Worldwide Associates v. Zebco Corp., 175 F.3d 985, 50 USPQ2d 1607 (Fed. Cir. 1999) 2163 , 2163.05
Jolles, In re, 628 F.2d 1322, 206 USPQ 885 (CCPA 1980) 2107.01 , 2107.02 , 2107.03
Jolley, In re, 308 F.3d 1317, 64 USPQ2d 1901 (Fed. Cir. 2002) 2138.04 , 2138.06
Joly, In re, 376 F.2d 906, 153 USPQ 45 (CCPA 1967) 2107.01 , 2107.02
Jones, Ex parte, 62 USPQ2d 1206, 1208 (Bd. Pat. App. & Inter. 2001) 2120
Jones, In re, 162 F.2d 479, 74 USPQ 149 (CCPA 1947) 2117
Jones, In re, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992) 707.07(f) , 2143.01 , 2144 , 2144.08
Jones v. Hardy, 727 F.2d 1524, 220 USPQ 1021 (Fed. Cir. 1984) 2141.02 , 2144.08
Jones v. Progress Ind., Inc., 163 F. Supp. 824, 119 USPQ 92 (D. R.I. 1958) 1504.02 , 1504.03
Josserand, In re, 188 F.2d 486, 89 USPQ 371 (CCPA 1951) 2133.03(e)(1)
Jovanovics, Ex parte, 211 USPQ 907 (Bd. Pat. App. & Inter. 1981) 2107.03
Joy Mfg. Co. v. National Mine Service Co., 810 F.2d 1127, 1 USPQ2d 1627 (Fed. Cir. 1987) 2246
Joy Technologies Inc. v. Manbeck, 751 F. Supp 225, 17 USPQ2d 1257 (D.D.C. 1990) 716.03(a)
J. P. Stevens & Co. v. Lex Tex Ltd., 747 F.2d 1553, 223 USPQ 1089 (Fed. Cir. 1984) 2016
Judin v. United States, 110 F.3d 780, 42 USPQ2d 1300 (Fed. Cir. 1997) 410
Juicy Whip Inc. v. Orange Bang Inc., 185 F.3d 1364, 51 USPQ2d 1700 (Fed. Cir. 1999) 2104
Jung, In re, 637 F.3d 1356, 98 USPQ2d 1174 (Fed. Cir. 2011) 1205.02 , 1207.03 , 1504.01(c)
Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330, 2021 USPQ2d 893 (Fed. Cir. 2021) 2163
Justus v. Appenzeller, 177 USPQ 332 (Bd. Pat. Inter. 1971) 2138.06
Cited authority
- 2164.06 Quantity of Experimentation
- 2164.06(a) Examples of Enablement Issues-Missing Information
- 2404.02 Biological Material That Can Be Made or Isolated Without Undue Experimentation
- 1504 Examination
- 2133.03(b) “On Sale”
- 2111.03 Transitional Phrases
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2111.02 Effect of Preamble
- 804.01 Prohibition of Nonstatutory Double Patenting Rejections Under 35 U.S.C. 121
- 1481.03 Correction of 35 U.S.C. 119 and 35 U.S.C. 120 Benefits
- 2258 Scope of Ex Parte Reexamination
- 2128 “Printed Publications” as Prior Art
- 2152.02(e) Otherwise Available to the Public
- 2144.04 Legal Precedent as Source of Supporting Rationale
- 2105 Patent Eligible Subject Matter — Living Subject Matter
- 2106.04(b) Laws of Nature, Natural Phenomena & Products of Nature
- 1504.03 Nonobviousness
- 804.02 Avoiding a Double Patenting Rejection
- 1490 Disclaimers
- 1605 Specification and Claim
- 2121.04 Apparatus and Articles — What Constitutes Enabling Prior Art
- 2125 Drawings as Prior Art
- 2165.01 Considerations Relevant to Best Mode
- 2164.01(c) How to Use the Claimed Invention
- 2164.08 Enablement Commensurate in Scope With the Claims
- 2173.05(i) Negative Limitations
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made
- 716.02(e) Comparison With Closest Prior Art
- 2173.02 Determining Whether Claim Language is Definite
- 2163.05 Changes to the Scope of Claims
- 2107.01 General Principles Governing Utility Rejections
- 2107.02 Procedural Considerations Related to Rejections for Lack of Utility
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 2138.04 “Conception”
- 2138.06 “Reasonable Diligence”
- 2120 Rejection on Prior Art
- 2117 Markush Claims
- 707.07(f) Answer All Material Traversed
- 2143.01 Suggestion or Motivation To Modify the References
- 2144 Supporting a Rejection Under 35 U.S.C. 103
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 2141.02 Differences Between Prior Art and Claimed Invention
- 1504.02 Novelty
- 2133.03(e)(1) Commercial Exploitation
- 2246 Decision Ordering Reexamination under 35 U.S.C. 304
- 716.03(a) Commercial Success Commensurate in Scope With Claimed Invention
- 2016 Fraud, Inequitable Conduct, or Violation of Duty of Disclosure Affects All Claims
- 410 Representations to the U.S. Patent and Trademark Office
- 2104 Requirements of 35 U.S.C. 101
- 1205.02 Appeal Brief Content
- 1207.03 New Ground of Rejection in Examiner’s Answer
- 1504.01(c) Lack of Ornamentality